Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

European Medicines Agency rejects call for insulin review

The European Medicines Agency has rejeccted a call by the European Association for the Study of Diabetes for an investigation into a link between insulin glargine treatment and the development of cancer.

In July four papers and an editorial in Diabetologia concluded the link 'required further investigation'.

But a review by the agency's Committee for Medicine Products for Human Use concluded 'the available data does not provide a cause for concern and changes to prescribing advice are unnecessary.'

Professor Stuart Pocock, professor of epidemiology at the London School of Hygiene and Tropical Medicine, wrote in The Lancet that the trials had been methodologically flawed and may have caused patients 'unnecessary alarm and anxiety.'

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say